Cassava Sued Over Alzheimer’s Drug Data Manipulation Allegations

A Cassava Sciences Inc. investor sued it in Delaware over claims that the biotech company may have manipulated its data after clinical trials of its sole drug candidate, a potential treatment for Alzheimer’s disease.

The lawsuit, filed Monday in Delaware Chancery Court, seeks internal files from Cassava to investigate data manipulation allegations made by a whistleblower, a market analyst, the media, and other shareholders that recently initiated federal securities fraud litigation in Austin, Texas.

It accuses the company of refusing to turn over documents—defying a state law that gives shareholders broad inspection rights if they credibly suspect wrongdoing—after negotiating a ...